HOUSTON--(BUSINESS WIRE)--Vyripharm Enterprises Inc. (VEI), a Texas biopharmaceutical/biotechnology company based in the Texas Medical Center (TMC) in Houston, and ABB Robotics, a leading global technology company headquartered in Zürich, Switzerland, have signed an agreement towards the development of an automated laboratory testing platform.
US based Vyripharm International has executed a memorandum of understanding (MoU) with National Yang-Ming University (NYMU), a research institution in Taipei, Taiwan.
US based Vyripharm International has executed a memorandum of understanding (MoU) with National Yang-Ming University (NYMU), a research institution in Taipei, Taiwan.
HOUSTON--(BUSINESS WIRE)--Vyripharm Biopharmaceuticals, a subsidiary of Vyripharm Enterprises, LLC, a privately held company located in the Texas Medical Center in Houston, Texas, announced today that it has signed off on a Master Drug Program Agreement with Regis Technologies, Inc. Regis is a privately held contract development manufacturing organization (CDMO) in Morton Grove, Illinois. The agreement allows Vyripharm to further develop its antiviral diagnostic agents to first-in-humans studies of viral infections such as SARS, MERS and COVID-19.